📣From lead to pre-candidate nomination in 18 months. Explore the STORM Therapeutics case study

Contact
  • Integrated Drug Discovery

    Integrated Drug Discovery

    Overview

    We deliver truly integrated drug discovery programs. Our co-located teams accelerate compounds from target ID to candidate.

  • Target Identification & Validation

    Target Identification & Validation

    It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.

  • Hit Identification

    Hit Identification

    Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.

  • Hit-to-Lead

    Hit-to-Lead

    High-quality hits with early proof of concept are de-risked and profiled, ready to accelerate your program towards lead optimization.

  • Lead Optimization

    Lead Optimization

    Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.

Featured Resources

  • Modalities

    Modalities

    Overview

    Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.

  • Small Molecules

    Small Molecules

    Expert small molecule discovery from target ID to scale-up, delivering candidates designed for success and market impact.

  • Peptides

    Peptides

    Transforming complex peptide concepts into next-generation therapies through integrated design, advanced analytics, and collaborative end-to-end discovery expertise.

  • Targeted protein degradation

    Targeted protein degradation

    Leveraging induced proximity and CHARMED technology to rapidly design, test, and optimize degraders for previously ‘undruggable’ targets.

  • ADCs

    ADCs

    Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.

  • Biologics

    Biologics

    Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.

Featured Resources

  • Therapeutic Areas

    Therapeutic Areas

    Overview

    Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.

  • Oncology and Immuno-Oncology

    Oncology and Immuno-Oncology

    Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.

  • Inflammation and Immunology

    Inflammation and Immunology

    Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.

  • Neuroscience

    Neuroscience

    Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.

  • Metabolic Diseases

    Metabolic Diseases

    Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.

Featured Resources

  • CellCentric Lead Optimisation Campaign - CCS1477

    CellCentric Lead Optimisation Campaign - CCS1477

    Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.

    Case study
  • About Sygnature

    About Sygnature

    At Sygnature Discovery, we deliver world-leading drug discovery solutions to accelerate your compound from idea to clinic.

  • Meet our Team

    Meet our Team

    Our leadership team brings diverse experience and insight, driving collaboration and innovation across drug discovery.

  • Careers

    Careers

    Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.

Search Results

Search across news, resources and pages to quickly find relevant content on our site.

Loading…
Blog
To kill a cancer cell… or not?
There’s a common adage that “the best cancer cell is a dead cancer cell”. However,…
Blog
Crossing the Great Divide: the shadowy issue of secondary brain cancers
Dr Allan Jordan, Head of Oncology at Sygnature Discovery, shares his thoughts on this significant…
Blog
EBOOK: A journey through anti-inflammatory drug discovery
Embark on an insightful journey through anti-inflammatory drug discovery in our new ebook. Join Dr. John Unitt, Director of Bioscience, as he unveils key landmarks, current treatments, and future therapeutic directions. Explore the crucial world of anti-inflammatory research now.
Blog
Walking the tightrope – exploiting delicate balances in cancer therapeutics
The dosing of cancer therapeutics to patients is often described as a delicate balance of…
News
Sygnature Discovery wins Medilink Outstanding Achievement Award
Sygnature Discovery emerged victorious at the Medilink UK Healthcare Virtual Business Awards 2020, securing…
Blog
The art of selecting the best HTS hits through biophysics
By its very nature, a small molecule HTS identifies large numbers of potential hits, and…
Blog
The dietary-induced obese (DIO) mouse: A robust platform for the development of anti-obesity pharmacotherapies
There is a growing need for efficacious anti-obesity treatments that produce clinically…
Blog
What makes a successful small biotech?
by Stuart Onions – Senior Vice-President, Alliance Management As always,…
Blog
Abuse liability assessments… how to get what you want
Why the beginning may be a very bad place to start…
Blog
How to trust your data: the power of statistical analysis in in vivo experimental design
Embarking on an in vivo proof of concept study without the right statistical support can…
News
What happened? A 2020 Recap!
It’s been a year the world will not soon forget. We’ve all had to adapt,…
Journal Papers
Sensitivity of Binding Free Energy Calculations to Initial Protein Crystal Structure
Miroslav Suruzhon, Michael S Bodnarchuk, Antonella Ciancetta, Russel Viner, Ian D Wall, and Jonathan W…
Blog
Often overlooked, but not forgotten – delivering better cancer medicines for children
Cancer incidence is intimately intertwined with advancing age. But as Allan Jordan, Sygnature Discovery’s Director…
News
Dr Paul Overton becomes Chief Commercial Officer (CCO) at Sygnature Discovery
Dr Paul Overton has been named as Sygnature’s first Chief Commercial…
News
Sygnature upgrades western blotting capability with Jess instrument from Protein Simple
Sygnature Elevates Western Blotting Capabilities with Innovative Simple Western™ Jess Instrument Sygnature Discovery has taken…
News
Sygnature Discovery shortlisted for BioNow Company of the Year Award
Sygnature Discovery is pleased to announce that we are a finalist for Company of the…
Blog
Rethinking Diabetes Drug Discovery
The diabetes pandemic is a reality which currently affects around 462 million…
News
Enhancing Molecular Design Services: Sygnature Discovery Adopts OpenEye’s Orion™ Platform
Sygnature Accelerates Customers’ Drug Discovery Timelines with Improved Hit Identification, Lead Optimisation Capabilities Sygnature has…
Journal Papers
Targeting p300/CBP axis in lethal prostate cancer
Jonathan Welti, Adam Sharp, Nigel Brooks, Wei Yuan, Christopher McNair, Saswati N Chand, Abhijit Pal,…
Blog
Psychedelics, a new frontier for mental health treatments
For cultural reasons, psychedelics have had something of a bad reputation. But over recent years…
News
Sygnature Discovery named Company of the Year at Bionow Annual Awards
Sygnature Discovery is thrilled to announce that we have been named Company of the Year at the Bionow…
Load More

Support

Can't find what you're looking for?

Can't find what you're looking for? Our team can help — whether you need assistance locating a resource, have a research enquiry, or want media information, get in touch and we'll point you in the right direction.

Get in touch